Amgen Inc. (AMGN)

NASDAQ: AMGN · USD

$379

-6.28 (-1.6%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-04 02:00 UTC. Latest published research analyzed 2026-05-08 · historical · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh AMGN analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-08

Our latest published analysis: AMGN rated Strong Buy

AMGN is rated Strong Buy at $329.09 versus the reconciled fair value midpoint of $505.34, implying +53.56% upside/downside. Confidence is separately disclosed at 88/100.

Fair value (mid)

$505 / share

$367 – $644

Upside to FV

+53.6%

from $379

Confidence

88/100

Moat

9/10

Read full analysis

Market cap	$177.7B
Revenue (ttm)	37.2B
Net income (ttm)	7.8B
EPS (ttm)	$14.4
Shares out	539.7M
P/E (trailing)	26.4x
P/E (forward)	14.0x
Dividend	$10.1 (2.66%)
Volume	3,443,059
Beta	0.40
Price target	$357	-5.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 37.2B
Net income (ttm): 7.8B
EPS (ttm): $14.4
P/E (trailing): 26.4x
P/E (forward): 14.0x
Market cap: $177.7B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$26.32B	$28.19B	$33.42B	$36.75B	+11.8%
Gross profit	$19.92B	$19.74B	$20.57B	$24.71B	+7.5%
Operating income	$9.57B	$7.90B	$7.26B	$9.08B	-1.7%
Net income	$6.55B	$6.72B	$4.09B	$7.71B	+5.6%
EPS (diluted)	$12.11	$12.49	$7.56	$14.23	+5.5%
EBITDA	$12.17B	$14.80B	$13.36B	$16.90B	+11.6%
R&D	$4.43B	$4.78B	$5.96B	$7.27B	+17.9%
SG&A	$5.41B	$6.18B	$7.10B	$7.05B	+9.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	4.4T	34.8x	9.5x	101.6%	+6.1%	+50.5%	Sell
ABNB	Airbnb Inc.	89.4B	36.9x	7.1x	15.9%	+29.9%	+17.7%	Hold
ADBE	Adobe Inc.	99.9B	14.4x	4.0x	60.7%	+11.9%	-27.7%	Strong Buy
ABBV	AbbVie Inc.	433B	69.2x	6.7x	17.3%	+3.7%	+29.4%	Hold
ABT	Abbott Laboratories	185.4B	34.7x	4.0x	7.5%	+3.0%	-13.9%	Strong Buy
BIIB	Biogen Inc.	29.8B	35.8x	3.0x	8.9%	-3.0%	+53.0%	Strong Buy

All AMGN indicators

Market & fundamental data

Available fields

294

Groups with data

Currency

USD

Showing 294 of 294 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000318154
Company name	Amgen Inc.
Country	United States
Country code	US
Cusip	031162100
Employees	31,500
Employees Change	3,500%
Employees Change Percent	12.5
Enterprise value	$249.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
In Index	SP500, NASDAQ100, DOW30
Industry	Drug Manufacturers - General
Industry PE	27.27
Industry PE Fwd	18.65
Isin	US0311621009
Last refreshed	2026-08-04
Market cap	$204.5B
Market cap category	Mega-Cap
Price	$379
Price currency	USD
Rev Per Employee	1,181,587.3x
Sector	Healthcare
Sector PE	44.08
Sector PE Fwd	23.8
Sic	2836
Symbol	AMGN
Tags	pharmaceuticals
Website	https://www.amgen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.81%
EV Earnings	32.02x
EV Sales Forward	6.56x
EV/EBIT	23.63x
EV/EBITDA	16.15x
EV/FCF	29.05x
EV/Sales	6.71x
FCF yield	4.2%
Forward P/E	16.78x
P/B ratio	22.25x
P/E ratio	26.37x
P/S ratio	5.49x
PE Ratio10 Y	25.07x
PE Ratio3 Y	28.82x
PE Ratio5 Y	25.59x
PEG ratio	3.6x
PS Forward	5.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	28.39%
EBITDA Margin	41.55%
FCF margin	23.1%
Gross margin	71.44%
Gross Profit	$26.6B
Gross Profit Growth	12.82%
Gross Profit Growth Q	10.41%
Gross Profit Growth3 Y	10.66%
Gross Profit Growth5 Y	6.92%
Net Income	$7.8B
Net Income Growth	31.47%
Net Income Growth Q	5.15%
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Net Income Growth3 Y	-0.5%
Net Income Growth5 Y	1.94%
Pretax Margin	24.41%
Profit Margin	20.96%
Profit Per Employee	$247,619
Profitable Quarters	$8
Profitable Years	23
ROA	8.35
Roa5y	8.22
ROCE	15.64
ROE	101.3
Roe5y	101.8
ROIC	19.05
Roic5y	20.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.36%
Cagr15y	17.03%
Cagr1y	31.48%
Cagr20y	10.94%
Cagr3y	21.71%
Cagr5y	13.09%
Div CAGR10	10.12%
Div CAGR3	6.07%
Div CAGR5	7.64%
EPS Growth	31.3
EPS Growth Q	4.38
EPS Growth Quarters	5
EPS Growth Years	1
EPS Growth3 Y	-0.8
EPS Growth5 Y	3.54
FCF Growth	-21.24%
FCF Growth Q	50.71%
FCF Growth3 Y	4.51%
FCF Growth5 Y	-2.65%
OCF Growth	-11.78%
OCF Growth Q	57.37%
OCF Growth10 Y	0.57%
OCF Growth3 Y	7.65%
OCF Growth5 Y	0.55%
Revenue Growth	9.07x
Revenue Growth Q	5.76x
Revenue Growth Quarters	12x
Revenue Growth Years	6x
Revenue Growth3 Y	12.43x
Revenue Growth5 Y	8.14x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.41
Assets	$92.5B
Cash	$12B
Current Assets	$31.5B
Current Liabilities	$25B
Debt	$57.3B
Debt EBITDA	$3.71
Debt Equity	$6.24
Debt FCF	$6.67
Equity	$9.2B
Interest Coverage	3.41
Liabilities	$83.3B
Long Term Assets	$61B
Long Term Liabilities	$58.4B
Net Cash	$-45.3B
Net Cash By Market Cap	$-22.15
Net Debt EBITDA	$2.93
Net Debt Equity	$4.93
Net Debt FCF	$5.27
Tangible Book Value	$-30.9B
Tangible Book Value Per Share	$-57.19
WACC	6.07

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.26
Inventory Turnover	1.65
Net Working Capital	$-81M
Quick ratio	0.85
Working Capital	$6.5B
Working Capital Turnover	$7.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.09%
Dividend Growth	5.86%
Dividend Growth Years	15%
Dividend per share	$10.08
Dividend Years	16
Dividend Yield	2.66%
Ex Div Date	2026-08-21
Last Dividend	$2.52
Payout Frequency	Quarterly
Payout Ratio	70.15%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	193.14%
1Y total return	31.45%
200-day SMA	344.3
3Y total return	80.3%
50-day SMA	356.7
50-day SMA vs 200-day SMA	50over200
5Y total return	84.94%
All Time High	398
All Time High Change	-4.81%
All Time High Date	2026-07-28
All Time Low	0.08
All Time Low Change	485,008.83%
All Time Low Date	1984-11-19
ATR	10.09
Beta	0.4
Beta1y	0.14
Beta2y	0.32
Ch YTD	15.75
High	391
High52	398
High52 Date	2026-07-28
High52ch	-4.81%
Low	376
Low52	269.8
Low52 Date	2025-09-26
Low52ch	40.44%
Ma50ch	6.22%
Premarket Change Percent	0.84
Premarket Price	$388
Premarket Volume	20,181
Price vs 200-day SMA	10.06%
RSI	58.1
RSI Monthly	61.67
RSI Weekly	62.86
Sharpe ratio	1.01x
Sortino ratio	1.94
Total Return	2.57%
Tr YTD	17.44
Tr15y	958.65%
Tr1m	1.26%
Tr1w	0.69%
Tr3m	15.74%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	34
Analyst Count Top	16
Analyst Price Target Top	$359
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$5.6
Earnings EPS Estimate Growth	-6.98
Earnings Revenue Estimate	9,424,962,280x
Earnings Revenue Estimate Growth	2.68x
Operating Income	$12.1B
Operating Income Growth	18.32
Operating Income Growth Q	24.43
Operating Income Growth3 Y	8.22
Operating Income Growth5 Y	5.8
Operating margin	32.63
Price target	$357
Price Target Change	$-5.76
Price Target Change Top	$-5.26

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	538,225,644%
Float Percent	99.73%
Net Borrowing	16,000,000
Shares Insiders	0.17%
Shares Institutions	82.83%
Shares Out	539,708,274
Shares Qo Q	0.18%
Shares Yo Y	0.09%
Short Float	2.39%
Short Ratio	4.66
Short Shares	2.38

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$8.1B
Adjusted OCF	10,272,000,000
Average Volume	2,362,728.65x
Bv Per Share	17.03
CAPEX	$-2.2B
Ch10y	117.6
Ch15y	610.7
Ch1m	1.26
Ch1w	0.69
Ch1y	27.62
Ch20y	435.4
Ch3m	14.87
Ch3y	64.43
Ch5y	58
Ch6m	9.92
Change	-1.63%
Change From Open	-2.48
Close	385.2
Days Gap	0.87
Depreciation Amortization	4,772,000,000
Dollar Volume	1,304,471,763.3
Earnings Date	2026-08-04
Earnings Time	amc
EBIT	$10.6B
EBITDA	$15.5B
EPS	$14.37
F Score	8
FCF	$8.6B
FCF EV Yield	3.44x
FCF Per Share	$15.93
Financing CF	-5,316,000,000
Fiscal Year End	December
Founded	1,980
Goodwill	18,674,000,000
Graham Number	74.19526
Graham Upside	-80.42
Income Tax	$1.3B
Investing CF	-2,212,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-08-04
Last Report Date	2026-03-31
Last Split Date	1999-11-22
Last Split Type	Forward
Last10k Filing Date	2026-02-13
Lynch Fair Value	$71.84
Lynch Upside	-81.04
Ma150	352.1
Ma150ch	7.6%
Ma20	371.4
Ma20ch	2.02%
Net CF	3,228,000,000
Next Earnings Date	2026-11-03
Open	388.5
Optionable	Yes
P FCF Ratio	23.78
P FCF Ratio SBC	25.2
P OCF Ratio	19.01
P OCF Ratio SBC	19.91
Payment Date	2026-09-11
Position In Range	19.31
Post Close	378.9
Postmarket Change Percent	0.64
Postmarket Price	$381
Ppne	8,216,000,000
Pre Close	385.2
Price Date	2026-08-03
Price EBITDA	$13.22
Relative Volume	1.46x
Revenue	37,220,000,000x
SBC By Revenue	1.3x
Share Based Comp	484,000,000
Tax By Revenue	3.46x
Tax Rate	14.16%
Tr20y	697.47%
Tr6m	11.52%
Us State	California
Views	258
Volume	3,443,059
Z Score	1.75

Frequently asked questions

About this AMGN report

What is the latest published AMGN stock rating?

Amgen Inc. is shown with strong buy in the latest published report, analyzed 2026-05-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AMGN analysis?

The full latest published report, analyzed 2026-05-08, lives at /stocks/AMGN/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for AMGN?

The latest published report analyzed 2026-05-08 frames AMGN around USD 367 to USD 644. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the AMGN page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Amgen Inc. (AMGN)

Coverage state: Latest published research available

Generate a fresh AMGN analysis

Our latest published analysis: AMGN rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AMGN

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All AMGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AMGN

Frequently asked questions